Viemed Healthcare (VMD) Expected to Post Earnings on Monday

Viemed Healthcare (NASDAQ:VMD) is projected to issue its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of $0.10 per share and revenue of $78.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Viemed Healthcare had a net margin of 5.20% and a return on equity of 10.52%. The firm had revenue of $75.41 million during the quarter, compared to the consensus estimate of $74.40 million. On average, analysts expect Viemed Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Viemed Healthcare Trading Down 0.8%

VMD opened at $11.67 on Friday. Viemed Healthcare has a twelve month low of $5.93 and a twelve month high of $12.61. The company has a quick ratio of 1.10, a current ratio of 1.22 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $11.12 and a 200-day moving average of $9.65. The stock has a market cap of $447.43 million, a PE ratio of 31.54 and a beta of 1.10.

Insider Buying and Selling

In other news, insider William Frazier sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $11.72, for a total transaction of $117,200.00. Following the completion of the sale, the insider owned 73,214 shares of the company’s stock, valued at $858,068.08. This trade represents a 12.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy Smokoff sold 20,000 shares of Viemed Healthcare stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total transaction of $230,000.00. Following the completion of the sale, the director owned 75,518 shares of the company’s stock, valued at $868,457. This represents a 20.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Viemed Healthcare

Large investors have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. bought a new stake in Viemed Healthcare in the fourth quarter valued at $46,000. Quarry LP acquired a new position in shares of Viemed Healthcare during the third quarter valued at about $48,000. AQR Capital Management LLC bought a new position in shares of Viemed Healthcare during the 1st quarter worth about $90,000. Invesco Ltd. boosted its position in shares of Viemed Healthcare by 25.5% during the 2nd quarter. Invesco Ltd. now owns 18,652 shares of the company’s stock worth $129,000 after purchasing an additional 3,795 shares in the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Viemed Healthcare by 52.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,565 shares of the company’s stock valued at $138,000 after buying an additional 6,408 shares during the period. 74.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Viemed Healthcare in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.